FAQ: Kairos Pharma Ltd.'s Advancements in Lung Cancer Biomarker Research and Clinical Trials

What is Kairos Pharma Ltd. focusing on with its recent DoD grant?

Kairos Pharma Ltd. is focusing on advancing lung cancer biomarker research with its recent DoD grant, alongside progressing clinical trials for its lead candidate ENV105 in prostate and EGFR-dependent non-small cell lung cancers.

What are the expected timelines for the safety and interim efficacy results of ENV105?

Safety and interim efficacy results for ENV105 are expected in Q2 2025, as the company advances its clinical trials.

What is KROS101 and what recent developments have been made?

KROS101 is an immune response modulator being developed by Kairos Pharma, with recent data presented at key oncology conferences.

How is Kairos Pharma Ltd. financially supporting its research and development?

Kairos Pharma Ltd. is supported by non-dilutive government grants, an expanding trial network, and analyst coverage from firms including EF Hutton and HC Wainwright, emphasizing its strong financial position.

What is the significance of ENV105 in cancer treatment?

ENV105 is significant as it targets CD105, a protein that drives resistance to various cancer treatments, aiming to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.

Where can I find more information about Kairos Pharma Ltd. and its developments?

More information can be found on the company’s website at www.KairosPharma.com or in the company’s newsroom at https://ibn.fm/KAPA.

What types of cancer is ENV105 currently being tested for?

ENV105 is currently in a Phase 2 clinical trial for castrate resistant prostate cancer and a Phase 1 trial for lung cancer.

Who is the CEO of Kairos Pharma Ltd.?

The CEO of Kairos Pharma Ltd. is John Yu, M.D., who recently issued a shareholder letter outlining the company’s progress and strategic developments.

What makes Kairos Pharma Ltd.’s approach to cancer treatment unique?

Kairos Pharma Ltd. utilizes structural biology to overcome drug resistance and immune suppression in cancer, focusing on targeting key drivers of resistance like CD105 with its lead candidate ENV105.